At the end of the quarter, our deferred revenue balance total on the balance sheet was approximately 54,700,000 dollars That reflects partnership revenue that we expect to receive over the next several years, excluding the receipt of any potential future milestones. And then quickly with respect to operating expenses, R and D for the quarter totaled $53,000,000 of that about $5,300,000 was non cash stock based compensation. The adjusted cash R and D spend of $47,700,000 excluding that stock based comp was up 13% from the comparable quarter a year ago. On the G and A side, our spending for the quarter was $14,200,000 of which $5,600,000 was non cash stock based comp and that adjusted G and A spend of $8,600,000 again excluding stock based comp is a 5% increase year over year. And then finishing up with our cash balances stated earlier, at the end of 2023, it was $436,000,000 including the $300,000,000 of net proceeds from our equity offering last month and the $15,000,000 that I referenced from Sanofi that was received early this year that brought our unaudited cash and equivalent balance as of January 9 to approximately $745,000,000 That is expected to provide a runway into the first half of twenty twenty seven and it will enable us to deliver the next stage of growth and data readouts including as Jared mentioned the KT-four seventy four Phase 2 data, our oncology proof of concept results this year and then several critical and clinical inflection points for our STAT6 and TYK2 programs.